pressures in the clinic, it would be useful to clinicians and patients if a set of patient-friendly definitions could be generated for the most common drug development endpoints.
In helping patients navigate terminology, there is a role for oncologists, members of the pharmaceutical industry, patient advocacy groups, nurses, and pharmacists to collaborate on generating and communicating patient-friendly language. The first step is to work with patients and advocacy groups to gain a better understanding of the problem. Definitions of common terms can then be generated in an iterative dialogue between patients, health care providers, and drug development scientists. Once an agreed-upon set of patient-friendly definitions is generated by various stakeholders, these definitions can be communicated in multiple ways, including web resources, provider education (including pharmacists and clinicians), and patient advocacy groups. The use of multiple sources of information for patients may help to mitigate the challenge of increasing time pressures at the point of care.
The role of the patient advocacy community is increasingly important. Patient advocates are well positioned to use their unique background and knowledge to help patients navigate through the health care system. Many patient advocates are acutely aware of the latest policy developments from regulatory agencies as well as the pharmaceutical industry and have built important communication lines to patients in order to receive feedback and provide information and guidance. Unfortunately, many patients are not aware that cancer advocacy groups can be an important and available resource. This is especially true for medically underserved populations, including racial and ethnic minorities and individuals of lower socioeconomic status, as their ability to access health care is often more limited [4] .
It is important to consider how we can improve the language we use with patients with cancer. A complete understanding of the risks and benefits of cancer therapies would allow patients and their families to make informed choices in their treatments. It is also important to be mindful of the patient as an individual and consider what specific terms Commentary need to be used when speaking with patients, as well as how and when to disseminate literature to patients. The FDA is committed to making oncology clinical trial endpoint terms more understandable to patients and has engaged patients in multiple venues to garner input on patiently friendly definitions for clinical trial endpoint terms. Several common endpoints and patient-friendly definitions were publicly discussed with patients and advocates at a 2018 FDA workshop entitled "Partners in Progress" [5] . In collaboration with providers, patients, pharmaceutical industry, caregivers, and patient advocates, we intend to further this work with a goal to develop a glossary of "patient-friendly" clinical trial endpoint terms and definitions for patients and providers to use. For example, based on our interaction with patients, we have generated a draft patient-friendly definition of progression-free survival as "the median length of time after the start of this treatment that patients are alive while their cancer does not grow or spread." Further discussions are needed to ensure that these patient-friendly definitions are understandable to patients and caregivers. The glossary could be expanded in the future to include other clinical trial terms that patients have difficulty understanding.
Our common goal shared among those in drug development and clinical care is to help patients and bring a patient focus to navigating their complex treatment journeys. Regulatory agencies, payers, health care providers, the pharmaceutical industry, and patient advocates all need to work together to direct patients to available resources and craft patient-friendly language that can help patients make truly informed treatment decisions.
